MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration

Satoshi O. Suzuki, Ryuhei Kitai, Josephine Llena, Sunhee C. Lee, James E. Goldman, Bridget Shafit-Zagardo

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

The MAP-2 isoform containing exon 13 (MAP-2e) is expressed in human fetal development as early as 15 gestational weeks and parallels oligodendrocyte maturation. MAP-2e is down-regulated following myelination and is expressed in few cells in the adult central nervous system (CNS). To determine whether CNS tumors express MAP-2e, we screened 122 archival, paraffin-embedded adult and pediatric tumors of the CNS and non-CNS. All oligodendrogliomas were positive and extensive staining was observed in glioblastomas, various malignant gliomas and dysembryoplastic neuroepithelial tumors. MAP-2e was not expressed in non-CNS tumors or neuroblastomas. Thus, neuroectodermal tumors that have glial characteristics express this developmental marker of immature glia. Analysis of oligodendrogliomas demonstrated numerous cell morphologies from round cells with no processes to cells with single or multiple processes. MAP-2e immunostaining also delineated tumor invasion into adjacent gray and white matter, indicating that MAP-2e appears to be a useful marker for examining the infiltration of malignant cells into surrounding tissue.

Original languageEnglish (US)
Pages (from-to)403-412
Number of pages10
JournalJournal of Neuropathology and Experimental Neurology
Volume61
Issue number5
DOIs
Publication statusPublished - Jan 1 2002

    Fingerprint

Keywords

  • Alternative splicing
  • Brain tumors
  • Glioblastoma
  • Immunohistochemistry
  • Microtubule-associated protein 2 (MAP-2)
  • Oligodendroglioma
  • Tumor infiltration

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this